These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Hake HS; Davis JKP; Wood RR; Tanner MK; Loetz EC; Sanchez A; Ostrovskyy M; Oleson EB; Grigsby J; Doblin R; Greenwood BN Physiol Behav; 2019 Feb; 199():343-350. PubMed ID: 30529341 [TBL] [Abstract][Full Text] [Related]
4. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Verrico CD; Miller GM; Madras BK Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332 [TBL] [Abstract][Full Text] [Related]
5. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter. Kramer HK; Poblete JC; Azmitia EC Neuropsychopharmacology; 1997 Sep; 17(3):117-29. PubMed ID: 9272479 [TBL] [Abstract][Full Text] [Related]
6. Progress and promise for the MDMA drug development program. Feduccia AA; Holland J; Mithoefer MC Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674 [TBL] [Abstract][Full Text] [Related]
7. MDMA induced dopamine release in vivo: role of endogenous serotonin. Koch S; Galloway MP J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077 [TBL] [Abstract][Full Text] [Related]
8. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Feduccia AA; Mithoefer MC Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):221-228. PubMed ID: 29524515 [TBL] [Abstract][Full Text] [Related]
9. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Baldo BA Arch Toxicol; 2024 Aug; 98(8):2409-2427. PubMed ID: 38743292 [TBL] [Abstract][Full Text] [Related]
10. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. Heifets BD; Salgado JS; Taylor MD; Hoerbelt P; Cardozo Pinto DF; Steinberg EE; Walsh JJ; Sze JY; Malenka RC Sci Transl Med; 2019 Dec; 11(522):. PubMed ID: 31826983 [TBL] [Abstract][Full Text] [Related]
11. Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice. Curry DW; Young MB; Tran AN; Daoud GE; Howell LL Neuropharmacology; 2018 Jan; 128():196-206. PubMed ID: 28993129 [TBL] [Abstract][Full Text] [Related]
12. Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. Lin CC; Tung CS; Liu YP Psychopharmacology (Berl); 2016 Apr; 233(7):1135-46. PubMed ID: 26740318 [TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. Maples-Keller JL; Norrholm SD; Burton M; Reiff C; Coghlan C; Jovanovic T; Yasinski C; Jarboe K; Rakofsky J; Rauch S; Dunlop BW; Rothbaum BO J Psychopharmacol; 2022 Mar; 36(3):368-377. PubMed ID: 35166140 [TBL] [Abstract][Full Text] [Related]
14. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Johansen PØ; Krebs TS J Psychopharmacol; 2009 Jun; 23(4):389-91. PubMed ID: 19273493 [TBL] [Abstract][Full Text] [Related]
15. Examining the Role of Oxytocinergic Signaling and Neuroinflammatory Markers in the Therapeutic Effects of MDMA in a Rat Model for PTSD. Avgana H; Toledano RS; Akirav I Pharmaceuticals (Basel); 2024 Jun; 17(7):. PubMed ID: 39065697 [TBL] [Abstract][Full Text] [Related]
16. Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors. Woodburn SC; Levitt CM; Koester AM; Kwan AC ACS Chem Neurosci; 2024 Aug; 15(16):3034-3043. PubMed ID: 39087917 [TBL] [Abstract][Full Text] [Related]
17. Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Frederick DL; Ali SF; Slikker W; Gillam MP; Allen RR; Paule MG Neurotoxicol Teratol; 1995; 17(5):531-43. PubMed ID: 8551999 [TBL] [Abstract][Full Text] [Related]
18. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder. Amoroso T J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955 [TBL] [Abstract][Full Text] [Related]
19. Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine. Johnson CB; Walther D; Baggott MJ; Baker LE; Baumann MH J Pharmacol Exp Ther; 2024 Sep; 391(1):22-29. PubMed ID: 38272669 [TBL] [Abstract][Full Text] [Related]
20. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Escubedo E; Abad S; Torres I; Camarasa J; Pubill D Neurochem Int; 2011 Jan; 58(1):92-101. PubMed ID: 21074589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]